New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

(2015) Philip D. Home et al.   DIABETES CARE

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

(2015) R. H. A. Becker et al.   DIABETES OBESITY & METABOLISM

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

(2015) G. B. Bolli et al.   DIABETES OBESITY & METABOLISM

7. Approaches to Glycemic Treatment

(2014)   DIABETES CARE

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

(2014) Matthew C. Riddle et al.   DIABETES CARE

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

(2014) Hannele Yki-Järvinen et al.   DIABETES CARE

Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

(2014) M. Shiramoto et al.   DIABETES OBESITY & METABOLISM

The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988-2010

(2013) S. Stark Casagrande et al.   DIABETES CARE

Basal insulin analogues in the management of diabetes mellitus: what progress have we made?

(2013) David R. Owens et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

(2013) Chantal Mathieu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Type 1 diabetes

(2013) Mark A Atkinson et al.   LANCET

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Simon Heller et al.   LANCET

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial

(2012) Yasuhiko Iwamoto et al.   Journal of Diabetes Investigation

Optimizing the Replacement of Basal Insulin in Type 1 Diabetes Mellitus: No Longer an Elusive Goal in the Post-NPH Era

(2011) Geremia B. Bolli et al.   Diabetes Technology & Therapeutics

Multifaceted Determinants for Achieving Glycemic Control: The International Diabetes Management Practice Study (IDMPS)

(2008) J. C.N. Chan et al.   DIABETES CARE